Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...

https://www.thehindubusinessline.com/companies/natco-pharma-launches-generic-semaglutide-injection-in-india/article70764288.ece Copy Natco Pharma has launched the ...

A federal appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic version of its blockbuster heart failure drug Entresto. The US Court of Appeals for ...

At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the ...

Novo Nordisk's India patent on semaglutide expires this week Move to trigger wave of cheaper generics from local drugmakers Concerns raised about misuse, uneven oversight HYDERABAD, March 19 (Reuters) ...

Indian drugmakers seized on the patent expiry for Novo Nordisk A/S's blockbuster weight-loss and diabetes medication to roll out cut-price generic versions in a nation with the third-largest ...

Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of Hormuz for the arrival of key inputs in drug manufacturing including petroleum-based materials, and for ...